GSTP1 Methylation Offers Promise but Remains Outside Routine Prostate Cancer Screening

Promoter hypermethylation of the GSTP1 gene is one of the most consistent molecular signatures found in prostate cancer, occurring in more than 90% of several prostatectomy cohorts and suppressing expression of an enzyme involved in cellular stress responses. Yet after more than two decades of investigation, the modification has not become a stand-alone screening or diagnostic test. A 2026 narrative review concludes that GSTP1 methylation has achieved partial clinical translation only within the multiplex tissue assay ConfirmMDx, while urinary and blood-based versions remain investigational and highly dependent on specimen handling, assay design, patient selection and the diagnostic pathway being evaluated.

The biological signal is striking. GSTP1 encodes the pi-class glutathione S-transferase, which participates in glutathione conjugation and protection against oxidative and genotoxic stress. The gene is strongly expressed in normal basal prostate cells, can be induced in proliferative inflammatory atrophy, and is frequently silenced in high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma. Experiments in prostate cancer cells showed that reversing promoter methylation restored both GSTP1 transcription and protein expression, while methylation of promoter constructs reduced promoter activity. This supports a direct relationship between the epigenetic alteration and transcriptional silencing, although restoring GSTP1 did not reverse the malignant growth of already transformed cells.

More recent tissue analysis indicates that methylation accumulates as prostate lesions evolve. In a study of normal epithelium, proliferative inflammatory atrophy, high-grade prostatic intraepithelial neoplasia and cancer from 32 prostatectomy specimens, 0.52% and 1.3% of evaluated CpG sites were methylated in normal and atrophic epithelium, compared with 24% in high-grade intraepithelial neoplasia and 51% in invasive carcinoma. Methylation clustered near the transcription start site and binding regions for AP1 and SP1 transcription factors. Separate studies have detected GSTP1 methylation in 91.1% of malignant tissues versus 5.4% of adjacent healthy tissue and in 97% of radical-prostatectomy tumors, establishing a powerful malignant–benign contrast in specimens rich in tumor DNA.

That strength comes with important qualifications. GSTP1 methylation appears early in carcinogenesis and is highly prevalent, meaning it may identify malignant prostate epithelium without reliably distinguishing consequential from indolent tumors. In a 2024 analysis, higher tumor methylation was associated with biochemical recurrence and metastatic relapse in univariable models, but the association did not remain independent after adjustment for established clinicopathological factors. The marker also exists in heterogeneous forms: partially methylated promoter alleles and different patterns in separate tumor foci can coexist. Which CpG sites an assay interrogates may therefore change not only whether a sample appears positive, but also the amount of signal measured. The review treats GSTP1 principally as a marker of malignant tissue, not a stand-alone measure of tumor aggressiveness.

Measurement conditions are equally consequential. Tissue contains the greatest proportion of tumor-derived DNA and consequently gives the most reproducible signal. In urine, prostate cells and nucleic acids can be recovered non-invasively, but collection method, prostate manipulation, preservatives, processing delays, temperature, pH, storage and DNA extraction all affect recovery. Urinary cell-free DNA is especially vulnerable to degradation and loss of short fragments. Clinical findings in 2000 already illustrated the gap between tissue and urine: one study detected methylated GSTP1 in 94% of tumors but only 36% of urine samples, with higher detection after prostate massage. Urine is therefore promising, but “urinary GSTP1 test” does not describe a single standardized measurement.

A recent 120-patient study suggests that a carefully controlled workflow can improve urinary performance. Among biopsy-referred patients, including 59 with cancer and 61 with benign prostatic hyperplasia, standardized post-examination first-void urine analysis reported 81.4% sensitivity, 83.6% specificity, 82.5% accuracy and an area under the receiver operating characteristic curve of 0.87. In the PSA grey zone of 4–10 nanograms per milliliter, the corresponding values were 87.5%, 86.2%, 86.7% and 0.90. These findings were encouraging but came from a retrospective, single-center cohort already selected for biopsy, and the endpoint was any biopsy-confirmed cancer rather than clinically significant disease defined as Grade Group 2 or higher. Comparison with PSA alone also did not establish that GSTP1 adds useful information beyond PSA density, risk calculators, multiparametric MRI and other biomarkers.

Blood-based results are more limited because circulating tumor DNA may account for about 1% or less of total cell-free DNA in localized disease. A 2023 meta-analysis of cell-free-DNA studies pooled 37% sensitivity and 97% specificity, with substantial heterogeneity, indicating that a positive result may be informative while a negative result cannot reliably exclude a small localized tumor. A smaller 2024 study illustrates the variation: GSTP1 methylation was detected in only 3 of 13 cancers, producing 23% sensitivity and 32% specificity among 39 biopsy-received men and 15 healthy controls. Adding RASSF1 improved both measures, whereas requiring GSTP1, RASSF1 and RASSF2 raised specificity to 83% but reduced sensitivity to 8%. Multigene testing therefore does not automatically produce simultaneous gains in sensitivity and specificity.

Assay technology has advanced from qualitative methylation-specific polymerase chain reaction to quantitative, digital and sequencing approaches, but the review cautions that greater molecular resolution has not yet yielded a uniformly validated stand-alone test. Quantitative assays can be affected by unmethylated CpG sites located within primer and probe sequences, especially in urine containing partially methylated epialleles. Bisulfite conversion remains practical for PCR assays but can damage scarce DNA; enzymatic conversion and third-generation sequencing can preserve molecular integrity while introducing greater cost and bioinformatics demands. A small single-molecule plasma study found that combinations of methylation patterns at GSTP1 and two other loci could improve discrimination, but its 20 cancer cases, 17 patients with benign prostatic hyperplasia and 18 healthy donors raised concerns about model overfitting. Prespecified targets, thresholds and independent validation are therefore essential.

The clearest clinical niche is the repeat-biopsy setting, where ConfirmMDx measures GSTP1, APC and RASSF1 methylation in histologically negative biopsy tissue to identify an epigenetic field effect associated with potentially unsampled cancer. The American Urological Association and Society of Urologic Oncology lists the assay among biomarkers available for this setting. Population screening, pre-MRI triage, assessment after equivocal imaging and risk refinement in the PSA grey zone remain proposed research contexts rather than established indications. For pre-biopsy studies, Grade Group 2 or higher cancer should be the principal endpoint, and prospective multicentre testing should compare GSTP1-assisted care with contemporary pathways that already include risk models, established biomarkers and multiparametric MRI. The decisive measure would be whether the assay reduces unnecessary biopsies or scans without increasing missed clinically significant cancers, rather than whether it merely improves stand-alone sensitivity, specificity or area under the curve.

Subject of Research: Review of GSTP1 promoter methylation as a prostate cancer detection biomarker and its clinical translation

Article Title: GSTP1 promoter hypermethylation in prostate cancer detection: current evidence, clinical positioning, and translational gaps

Article References: Joo, J.-L., Wong, R. S.-Y., Goh, B. H., & Ng, N. C.-S. (2026). GSTP1 promoter hypermethylation in prostate cancer detection: current evidence, clinical positioning, and translational gaps. Molecular Biology Reports, 53(1), Article 1777. https://doi.org/10.1007/s11033-026-13011-2

Image Credits: AI Generated

DOI: 10.1007/s11033-026-13011-2

Keywords: GSTP1 methylation, prostate cancer, DNA methylation, liquid biopsy, urine biomarkers, cell-free DNA, ConfirmMDx, prostate cancer screening, multiparametric MRI, clinical validation, GSTP1, promoter